TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7201837
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg antipyrine (phenazone) administered orally (p.o.)
Study: 7201837
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg antipyrine (phenazone) administered i.v. in smokers
Study: 7201837
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg antipyrine (phenazone) administered i.v. in non-smokers
Study: 7201837
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg antipyrine (phenazone) in smokers
Study: 30665829
Drug: telmisartan/amlodipine/rosuvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan/amlodipine/rosuvastatin (80 mg/10 mg plus 20 mg)
Study: 30665829
Drug: telmisartan/rosuvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan/rosuvastatin (80 mg plus 20 mg)
Study: 30665829
Drug: telmisartan/amlodipine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan/amlodipine (80 mg/10 mg)
Study: 27502582
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg to 90 mg escalation
Study: 27502582
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg steady dose
Study: 22238577
Drug: L-DOPA (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (0, 100/25, 200/50 mg, Sinemet)
Study: 18199500
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg daily for 8 weeks)
Study: 15121931
Drug: Parenteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral glutamine supplementation
Study: 28692301
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (3.5 mg or 140,000 IU biweekly for 8 weeks)
Study: 10626290
Drug: Maximal androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal androgen blockade (LHRH agonists combined with antiandrogens)
Study: 10626290
Drug: LH-RH analogues
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH analogues alone or in combination with antiandrogens
Study: 1560168
Drug: Antigen challenge
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen challenge (0.004 to 100 PNU/ml)
Study: 1560168
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antigen challenge (>= 1 PNU/ml) in atopic subjects
Study: 29903674
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant zoster vaccine (RZV) co-administered with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Study: 29903674
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of PPSV23 followed by RZV
Study: 15767215
Drug: Long-term stavudine
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term stavudine therapy (40 mg single dose)
Study: 15767215
Drug: Single-dose stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose stavudine treatment (40 mg)
Study: 12224599
Drug: Daily combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily combination of 60 mg soy isoflavones, 100 mg dong quai, and 50 mg black cohosh for 24 weeks
Study: 8714852
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel antagonists (Nicardipine, Verapamil, Diltiazem) administered by iontophoresis
Study: 8714852
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel antagonists (Nicardipine, Verapamil, Diltiazem) administered by iontophoresis in combination with lidocaine
Study: 8714852
Drug: Lidocaine administered
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administered alone
Study: 25293650
Drug: Psychotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy and pharmacotherapy sessions
Study: 19047293
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice daily for 28 days in each 4-week cycle
Study: 16944408
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg/bd)
Study: 11738097
Drug: one 250
Normalized name: dipyrone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 250 microg bolus + 250 microg/h infusion
Study: 11738097
Drug: three 250
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: three 250 microg boluses + 250 microg/h infusion
Study: 11738097
Drug: three 250
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: three 250 microg boluses + 500 microg/h infusion
Study: 9228962
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months
Study: 9228962
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin A supplementation with one dose of measles vaccine at age 9 months
Study: 9228962
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (100,000 IU) with two doses of measles vaccine at ages 6 and 9 months
Study: 9228962
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin A supplementation with two doses of measles vaccine at ages 6 and 9 months
Study: 9228962
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months (boys)
Study: 9228962
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months (girls)
Study: 7965439
Drug: 3-week regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-week regimen of benzathine penicillin G (1.2 million units every 3 weeks)
Study: 7965439
Drug: 4-week regimen
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week regimen of benzathine penicillin G (1.2 million units every 4 weeks)
Study: 26218586
Drug: Biphasic immediate‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic immediate‐release (IR)/extended‐release (ER) oxycodone (OC)/acetaminophen (APAP) 7.5/325 mg tablets, total dose 15/650 mg every 12 hours for 4.5 days
Study: 24637537
Drug: Abiraterone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone (1000 mg q.d.) plus low-dose prednisone (5 mg b.i.d.)
Study: 22240264
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) mobilized PBMNCs
Study: 21218679
Drug: Feeding with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding with oral support
Study: 21218679
Drug: Feeding without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feeding without oral support
Study: 14708875
Drug: Pulsatile electromagnetic
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile electromagnetic field treatment (applied for 5 days, two times daily for 30 minutes, magnetic induction: 3 mT, frequency: 4 Hz)
Study: 10533300
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost 50 micrograms/ml
Study: 1559192
Drug: Quinapril (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (2.5, 5, 10 or 20 mg bid for four weeks)
Study: 7106162
Drug: Methenamine mandelate
Normalized name: methenamine mandelate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine mandelate granules 4 g/day alone
Study: 7106162
Drug: Methenamine mandelate
Normalized name: methenamine mandelate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine mandelate granules 4 g/day with ascorbic acid 4 g/day
Study: 7106162
Drug: Methenamine mandelate
Normalized name: methenamine mandelate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine mandelate granules 4 g/day with ascorbic acid 4 g/day plus cranberry cocktail 1/day
Study: 30794302
Drug: Dexamethasone, 4
Normalized name: Dexamethasone, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 4 mg, orally twice daily (total daily dose 8 mg)
Study: 25267661
Drug: Primaquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (30 mg)
Study: 25267661
Drug: Dihydroartemisinin-piperaquine (120/960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (120/960 mg)
Study: 16159655
Drug: Pre‐incision infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐incision infiltration of 1.5 ml local anesthetic mixture with general anesthesia (n=30)
Study: 16159655
Drug: Pre‐incision infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐incision infiltration of 1.5 ml of 0.9% normal saline with general anesthesia (placebo, n=30)
Study: 7492158
Drug: Follow on
Normalized name: ReQuip Follow on Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow on formula milk containing 1.2 mg of iron per 100 ml
Study: 7036276
Drug: i.v. cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. cyclophosphamide (30 mg/kg) over a 6-day period
Study: 17531459
Drug: CP-CLA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-CLA (400 mug chromium, 1.8 g CLA in 2.4 g tonalin oil, n=19)
Study: 17531459
Drug: Placebo (<0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (<0.1 microg Cr, 2.4 g canola oil, n=16)
Study: 11775548
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B alone or combination with flucytosine therapy (Group I)
Study: 11775548
Drug: Intravenous fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fluconazole alone or combination with flucytosine (Group II)
Study: 11775548
Drug: Intrathecal amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal amphotericin B plus intravenous amphotericin B with or without intravenous fluconazole followed by oral fluconazole or itraconazole (Group III)
Study: 9056056
Drug: Flumazenil (Anexate)
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil (Anexate) 1 mg intravenously post bronchoscopy
Study: 3541415
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg isosorbide-5-mononitrate (IS-5-MN) daily
Study: 3541415
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 20 mg nifedipine retard daily
Study: 3541415
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both drugs for 2 weeks
Study: 30922018
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg) added to ISB with bupivacaine 0.3% and lidocaine 2%
Study: 30922018
Drug: Ketamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (50 mg) added to ISB with bupivacaine 0.3% and lidocaine 2%
Study: 23791822
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (0·9 mg/kg) plus standard care (n=1515)
Study: 10825599
Drug: 30,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30,000 IU vitamin A for 3 days just after each three doses of primary vaccination (Group I, n=24)
Study: 10825599
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral vitamin E for only 1 day after the injections for primary immunization (Group II, n=21)
Study: 10825599
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin after DPT vaccines (Group IV, n=23)
Study: 3907323
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem 120 to 180 mg, 2 times a day
Study: 3907323
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 to 50 mg, 2 times a day
Study: 3907323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diltiazem and hydrochlorothiazide
Study: 28851001
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention group received a psychoeducational treatment program after a 6-week introduction period alongside psychodynamic treatment.
Study: 28851001
Drug: Late intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late intervention group received psychoeducation 3 months after starting psychodynamic treatment.
Study: 24766760
Drug: Transition to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition to medication adoption
Study: 24766760
Drug: Pharmaceutical detailing
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical detailing
Study: 22573119
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (losartan/hydrochlorothiazide)
Study: 22573119
Drug: Maximal-dose ARB
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal-dose ARB therapy
Study: 18628657
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (EGb 761) 300 mg/d
Study: 12663296
Drug: Borage oil
Normalized name: Borage oil
DrugBank: Borage oil (DB11238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borage oil supplement (containing 100 mg GLA)
Study: 12663296
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil supplement (placebo)
Study: 1323954
Drug: Temafloxacin at
Normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin at 600 mg twice daily
Study: 1323954
Drug: Amoxicillin at
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin at 500 mg three times daily
Study: 6394068
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mgs bid administered during chemotherapy and continued in 43 patients for up to five years after termination of chemotherapy
Study: 31685792
Drug: Dapagliflozin and
Normalized name: Dapagliflozin and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin and metformin
Study: 31685792
Drug: Glimepiride and
Normalized name: glimepiride and pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride and metformin
Study: 25392325
Drug: GNbAC1 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNbAC1 (2 or 6 mg/kg)
Study: 21314870
Drug: Mirtazapine (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15-30 mg/day)
Study: 21314870
Drug: Paroxetine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10-20 mg/day)
Study: 18485414
Drug: Intraprostatic lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraprostatic lidocaine injection
Study: 16972105
Drug: 384 mg
Normalized name: Kuvan 500 MG (sapropterin 384 MG) Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 384 mg naltrexone base
Study: 16972105
Drug: Heroin doses
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin doses (0, 6.25, 12.5, and 25 mg, i.v.)
Study: 14521737
Drug: Reduced glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glutathione (30 mg/kg) in priming fluid
Study: 10764156
Drug: Post-CNS treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-CNS treatment
Study: 8616736
Drug: Physician's prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's prescription belief
Study: 6237662
Drug: Neuromuscular blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocking drugs with controlled ventilation
Study: 27755490
Drug: Morphine5 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine5 (5 mg morphine)
Study: 27755490
Drug: Morphine10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine10 (10 mg morphine)
Study: 27755490
Drug: Morphine15 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine15 (15 mg morphine)
Study: 24161321
Drug: Short dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short dual antiplatelet therapy (DAPT) regimen (6 months)
Study: 24161321
Drug: Long dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long dual antiplatelet therapy (DAPT) regimen (24 months)
Study: 24161321
Drug: Short and
Normalized name: ALLERGENIC EXTRACT,RAGWEED,SHORT AND TALL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short and long dual antiplatelet therapy (DAPT) regimens
Study: 16617757
Drug: Ropivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.125% with 1 microg/ml fentanyl
Study: 16617757
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% with 1 microg/ml fentanyl
Study: 7030578
Drug: Lofexidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine (0.2 to 1.6 mg/day)
Study: 7030578
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 to 1.6 mg/day)
Study: 28562733
Drug: Subarachnoid block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid block (2 ml of 0.5% bupivacaine)
Study: 25904073
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy prescribed at ED discharge
Study: 25904073
Drug: No antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihypertensive therapy prescribed
Study: 24152240
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg (30 mg for 1 week, then 60 mg for 5 weeks)
Study: 19668928
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (MM) supplementation (daily, 6 days/week)
Study: 19668928
Drug: Iron only
Normalized name: Iron only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron only (Fe) supplementation (daily, 6 days/week)
Study: 17615064
Drug: Nutrition supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition supplementation (50 g/day of micronutrient fortified foods)
Study: 15106797
Drug: 8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/day of water-soluble fiber from oat bran
Study: 11783254
Drug: Fuzheng Yiai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Yiai Decoction (FZYAD) combined with chemotherapy
Study: 2318222
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg b.i.d.)
Study: 2318222
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg b.i.d.)
Study: 368368
Drug: Carbuterol hydrochloride
Normalized name: Albuterol
DrugBank: Carbuterol (DB13625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbuterol hydrochloride 2 mg, three times daily
Study: 368368
Drug: Ephedrine sulfate
Normalized name: Ephedrine Sulfate
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine sulfate 25 mg, three times daily
Study: 29228822
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination capsule (600 mg) containing Terminalia chebula (200 mg), Commiphora mukul (200 mg), Commiphora myrrha (200 mg) taken 3 times a day for 3 months
Study: 29228822
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (600 mg toast powder) taken 3 times a day for 3 months
Study: 12787964
Drug: Glucosol (32mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosol (32mg daily for 2 weeks)
Study: 12787964
Drug: Glucosol (48mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosol (48mg daily for 2 weeks)
Study: 12787964
Drug: Glucosol (soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosol (soft gel capsule formulation)
Study: 12787964
Drug: Glucosol (dry‐powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosol (dry‐powder filled hard gelatin capsule formulation)
Study: 10826401
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8 to 16 mg)
Study: 16565237
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 to 20 mg)
Study: 10826401
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (12.5 to 25 mg)
Study: 6397541
Drug: Behaviourally-oriented weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviourally-oriented weight loss ('diet') programme administered by professional dietitians
Study: 3537101
Drug: Sodium ipodate
Normalized name: ipodate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ipodate (1 g daily for 10 days)